(Q28479036)

English

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses

scientific article

In more languages

Statements

scholarly article

0 references

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Donald F Smee

0 references

Menno D de Jong

6

object named as

Menno D de Jong

0 references

author name string

Jack T Nguyen

1

0 references

Dale L Barnard

3

0 references

Justin G Julander

4

0 references

Matthew Gross

5

0 references

Gregory T Went

7

0 references

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

1

0 references

e31006

0 references

copyright license

Creative Commons Attribution 4.0 International

23 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

19 March 2017

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

19 March 2017

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

19 March 2017

Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

19 March 2017

Enhancement of activity against influenza viruses by combinations of antiviral agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

19 March 2017

Oseltamivir resistance during treatment of influenza A (H5N1) infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

7 April 2017

H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Use of Oseltamivir to control influenza complications after bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

29 September 2017

The toxicologic and pharmacologic properties of amantadine hydrochloride.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

2 June 2018

Combinations of antiviral agents for treatment of influenza virus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

2 June 2018

Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0031006

21 January 2018

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0031006

21 January 2018

Fatal oseltamivir-resistant influenza virus infection

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0031006

21 January 2018

Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0031006

21 January 2018

Update: influenza activity--United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264642

27 November 2018

Identifiers

10.1371/JOURNAL.PONE.0031006

0 references

2012PLoSO...731006N

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28479036&oldid=2142182173"